Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
2024年1月4日 - 6:05AM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule product candidates to address serious
diseases, including oncology, obesity and non-alcoholic
steatohepatitis (NASH), today announced that it has granted as of
January 1, 2024 an equity inducement award to a new employee under
the terms of the 2022 Employment Inducement Award Plan, as amended
(the “Inducement Plan”). The equity award was approved by the
Compensation Committee of the Company’s Board of Directors in
accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a
material inducement to the employee’s acceptance of employment with
Terns.
The Company granted the employee options to purchase 19,000
shares of Terns common stock to the new employee. The options have
a 10-year term and an exercise price per share equal to $6.49,
which was the closing price of Terns’ common stock on December 29,
2023, the last trading day prior to the date of grant. The options
vest over four years, subject to the employee’s continued service
through the applicable vesting dates.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule product candidates to
address serious diseases, including oncology, obesity and NASH.
Terns’ pipeline includes three clinical stage development programs
including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1
receptor agonist, and a THR-β agonist, and a preclinical GIPR
modulator program. For more information, please
visit: www.ternspharma.com.
Contacts for Terns
InvestorsJustin
Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public
Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
過去 株価チャート
から 8 2024 まで 9 2024
Terns Pharmaceuticals (NASDAQ:TERN)
過去 株価チャート
から 9 2023 まで 9 2024